Your browser doesn't support javascript.
Mild SARS-CoV-2 Infections and Neutralizing Antibody Titers.
Bonfante, Francesco; Costenaro, Paola; Cantarutti, Anna; Di Chiara, Costanza; Bortolami, Alessio; Petrara, Maria Raffaella; Carmona, Francesco; Pagliari, Matteo; Cosma, Chiara; Cozzani, Sandra; Mazzetto, Eva; Di Salvo, Giovanni; Da Dalt, Liviana; Palma, Paolo; Barzon, Luisa; Corrao, Giovanni; Terregino, Calogero; Padoan, Andrea; Plebani, Mario; De Rossi, Anita; Donà, Daniele; Giaquinto, Carlo.
  • Bonfante F; Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, Padua, Italy FBonfante@izsvenezie.it.
  • Costenaro P; Division of Pediatric Infectious Diseases, Department for Women's and Children's Health, University of Padua, Padua, Italy.
  • Cantarutti A; Laboratory of Healthcare Research and Pharmacoepidemiology, Division of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
  • Di Chiara C; Division of Pediatric Infectious Diseases, Department for Women's and Children's Health, University of Padua, Padua, Italy.
  • Bortolami A; Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, Padua, Italy.
  • Petrara MR; Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padua, Padua, Italy.
  • Carmona F; Istituto Oncologico Veneto, IRCCS, Padua, Italy.
  • Pagliari M; Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, Padua, Italy.
  • Cosma C; Department of Laboratory Medicine, University Hospital of Padua, Padua, Italy.
  • Cozzani S; Division of Pediatric Infectious Diseases, Department for Women's and Children's Health, University of Padua, Padua, Italy.
  • Mazzetto E; Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, Padua, Italy.
  • Di Salvo G; Department for Women's and Children's Health, University of Padua, Italy.
  • Da Dalt L; Department for Women's and Children's Health, University of Padua, Italy.
  • Palma P; Academic Department of Pediatrics (DPUO), Research Unit of Clinical Immunology and Vaccinology, Bambino Gesù Children's Hospital, Rome, Rome, Italy.
  • Barzon L; Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.
  • Corrao G; Department of Molecular Medicine, University of Padua, Italy.
  • Terregino C; National Centre for Healthcare Research and Pharmacoepidemiology, University of Milano-Bicocca, Milan, Italy.
  • Padoan A; Laboratory of Healthcare Research and Pharmacoepidemiology, Division of Biostatistics, Epidemiology and Public Health, Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milan, Italy.
  • Plebani M; Division of Comparative Biomedical Sciences, Istituto Zooprofilattico Sperimentale delle Venezie, Padua, Italy.
  • De Rossi A; Department of Medicine-DIMED, University of Padua, Italy, Padua, Italy.
  • Donà D; Department of Medicine-DIMED, University of Padua, Italy, Padua, Italy.
  • Giaquinto C; Department of Laboratory Medicine, University Hospital of Padua, Padua, Italy.
Pediatrics ; 148(3)2021 09.
Article in English | MEDLINE | ID: covidwho-1280670
ABSTRACT

BACKGROUND:

Recent evidence suggests that neutralizing antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 may persist over time; however, knowledge regarding pediatric subjects is limited.

METHODS:

A single-center, prospective observational study was conducted on 57 family clusters of coronavirus disease 2019, including children of neonatal and pediatric age attending the University Hospital of Padua (Italy). For each patient, blood samples were collected for both the quantification of nAbs through a plaque reduction neutralizing test and the detection of antinucleocapsid-spike protein immunoglobulin G and/or immunoglobulin M.

RESULTS:

We analyzed 283 blood samples collected from 152 confirmed coronavirus disease 2019 cases (82 parents and 70 children or older siblings of median age of 8 years, interquartile range 4-13), presenting asymptomatic or with mildly symptomatic disease. Despite the decrease of immunoglobulin G over time, nAbs were found to persist up to 7 to 8 months in children, whereas adults recorded a modest declining trend. Interestingly, children aged <6 years, and, in particular, those aged <3 years, developed higher long-lasting levels of nAbs compared with older siblings and/or adults.

CONCLUSIONS:

Mild and asymptomatic severe acute respiratory syndrome coronavirus 2 infections in family clusters elicited higher nAbs among children.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Adolescent / Adult / Child / Child, preschool / Humans / Infant / Infant, Newborn Country/Region as subject: Europa Language: English Year: 2021 Document Type: Article Affiliation country: Peds.2021-052173

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Topics: Long Covid Limits: Adolescent / Adult / Child / Child, preschool / Humans / Infant / Infant, Newborn Country/Region as subject: Europa Language: English Year: 2021 Document Type: Article Affiliation country: Peds.2021-052173